BioCentury | Jun 26, 2020
Distillery Therapeutics

MAP3K7, IL18R1 as targets in obesity-related cerebrovascular dysfunction

DISEASE CATEGORY: Endocrine/metabolic; neurology INDICATION: Obesity; stroke Inhibiting MAP3K7 or the IL-18 receptor subunit IL18R1 could treat obesity-associated cerebrovascular dysfunction. In cultured rat aortic endothelial cells, an siRNA against IL18R1 increased levels of phosphorylated NOS3,...
BioCentury | Aug 9, 2019
Company News

Enbrel ruling lifts Amgen shares

A decision by the U.S. District Court for the District of New Jersey late Friday removed a key overhang on Amgen shares when it upheld two Enbrel patents at stake in a suit against Sandoz....
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Sep 14, 2018
Company News

Acorda loses Amprya appeal, reports Inbrija PDUFA delay

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $10.30 (37%) to $17.25 the week of Sept. 10 following setbacks related to multiple sclerosis drug Ampyra dalfampridine and Parkinson's disease candidate Inbrija levodopa inhalation powder (CVT-301). On Sept. 10,...
BioCentury | Sep 10, 2018
Company News

Acorda loses appeal to shield Ampyra from generic entry

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $6.75 (25%) to $20.80 Monday after the U.S. Court of Appeals for the Federal Circuit upheld a 2017 district court ruling that leaves multiple sclerosis drug Ampyra dalfampridine with no...
BioCentury | May 29, 2018
Preclinical News

IL-1 blockade to treat CAR T side effects

In a pair of papers published Monday in Nature Medicine, researchers from the Sloan Kettering Institute and the San Raffaele Hospital Scientific Institute suggest blocking the IL-1 receptor could help treat side effects of CAR...
BioCentury | May 23, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Patient sample and mouse studies suggest inhibiting NOS2 could help treat psoriatic arthritis. In peripheral blood mononuclear cells (PBMCs) from patients, levels of NOS2 were higher than in healthy volunteers. In a mouse...
BioCentury | Oct 31, 2017
Distillery Techniques

Biomarkers

...rs7757969), membrane associated guanylate kinase WW and PDZ domain containing 2 (MAGI2) (rs323167), neuronal nitric oxide synthase 1 (NOS1; nNOS...
...family tyrosine kinase (FYN) Membrane associated guanylate kinase WW and PDZ domain containing 2 (MAGI2) Neuronal nitric oxide synthase 1 (NOS1) (nNOS) Ras...
BioCentury | Oct 20, 2017
Company News

Federal judge invalidates four Restasis patents, slams Allergan's patent deal with tribe

On Oct. 16, a federal judge invalidated four patents covering dry-eye drug Restasis cyclosporine Allergan plc (NYSE:AGN) and questioned the pharma's patent deal with the Saint Regis Mohawk Tribe. Although the court found that Allergan...
BioCentury | Oct 16, 2017
Company News

Federal judge invalidates four Restasis patents

On Monday, Allergan plc (NYSE:AGN) sank $7.11 to $198.41 after a federal judge invalidated four patents covering its dry-eye drug Restasis cyclosporine. Although the court found that Allergan proved its case that a handful of...
Items per page:
1 - 10 of 778